What Do Ophthalmic Pharmaceuticals Cost?

A procurement-level guide to acquisition pricing, cost drivers, and negotiation levers across topical drops, biologics, and compounded agents — updated as MedSource aggregate quote data accrues.

Ophthalmic pharmaceuticals span one of the widest price bands in the institutional formulary — from compounded bevacizumab at roughly $55–$60 per intravitreal dose to branded anti-VEGF biologics at $1,850–$2,023 per injection, with branded topical prescriptions typically falling in the $150–$400 per bottle range and generic topicals at $10–$100. The primary cost driver is not therapeutic category but formulation type: a biologic intravitreal agent will cost 30–40 times more per administration than a functionally comparable off-label compounded alternative. Route of administration, brand status, preservative-free designation, and whether a biosimilar exists in the same therapeutic class are the four levers that account for most of the variance a procurement officer will encounter. Note: MedSource does not yet hold aggregate quote data for this category. All figures below are drawn from published wholesale acquisition cost (WAC) data, peer-reviewed pharmacoeconomic studies, FDA-published sources, and manufacturer-disclosed pricing. This article will be revised as institutional quotes accrue.

---

What the Typical Range Is

Ophthalmic pharmaceutical procurement spans three commercially distinct tiers:

Tier 1 — OTC lubricants and astringents (21 CFR Part 349): Eye drops are available by prescription or sold as over-the-counter (OTC) products. OTC artificial tears and lubricants carry retail acquisition costs of roughly $5–$30 per unit; institutional (case-quantity) pricing is typically 20–40% below that. These products are regulated, but non-prescription OTC eye drops are not FDA-approved — only prescription eye drops are FDA-approved in the full NDA/BLA sense.

Tier 2 — Topical Rx generics and branded drops (glaucoma agents, antibiotics, anti-inflammatories, dry-eye medications): The most frequently prescribed generic topical drugs are glaucoma medications (34%), antimicrobials (32%), and anti-inflammatories (24%); the most frequently prescribed branded topical drugs are anti-inflammatories (45%), glaucoma medications (32%), and antimicrobials (21%). Generic acquisition runs $10–$100 per bottle depending on volume purchased; branded topicals typically range from $150 to $400+ per bottle at WAC.

Tier 3 — Intravitreal anti-VEGF biologics (the dominant cost driver for retina programs): Aflibercept is approximately $1,850 per intravitreal dose, while ranibizumab 0.5 mg has a price tag of $1,950–$2,023 per dose.

Brolucizumab (Beovu) carries a retail price of approximately $1,997 per dose. In contrast, bevacizumab, repackaged at compounding pharmacies into syringes for ophthalmologic use containing 1.25 mg of bevacizumab, costs approximately $60 per dose — though its use is off-label for ophthalmic indications. Anti-VEGF agents accounted for the largest revenue share at 32.86% of the global ophthalmic drug market in 2024.

Across a multi-year treatment course, injection frequency matters as much as unit price: based on wholesale acquisition cost and projected injection frequency over the first three years of treatment, faricimab is less expensive than ranibizumab and aflibercept by $37,709 and $6,359, respectively.

---

What Pushes Price Up

1. Biologic and monoclonal antibody formulations. Key anti-VEGF examples include aflibercept, faricimab, bevacizumab, ranibizumab, and brolucizumab; several factors contribute to their significant market share, including proven efficacy and safety, a wide range of indications, long patent life, and high cost.

2. Chronic retinal disease burden. Given that retinal diseases are chronic, the usage of biologics tends to be higher, leading to a larger share of revenues due to the need for repeated injections. A single AMD patient requiring monthly injections can represent $20,000–$24,000 per year in drug acquisition cost at branded WAC.

3. Preservative-free (PF) formulations. PF single-dose vials carry a 25–60% WAC premium over preserved multi-dose equivalents because of higher fill-finish manufacturing costs. Preservatives play a crucial role in preventing microbial contamination, extending shelf life, and ensuring the safety of many eye drop products, especially multi-dose containers — PF products forgo this protection, requiring unit-dose packaging.

4. Recently approved branded agents. Incumbents maintain market share via high-dose or preservative-free extensions and device-enabled formulations that refresh patent life. Newly approved agents such as Roche's Susvimo (ranibizumab injectable implant) or Alcon's TRYPTYR carry launch-year pricing premiums before payer negotiations compress net pricing.

5. Regulatory compliance costs. Revised FDA aseptic-processing guidance in 2024 mandated enhanced environmental monitoring, adding 6–12 months to validation timelines, while EMA Annex 1 revisions and similar cleanroom upgrades can cost up to USD 20 million per site. Manufacturers pass these costs forward.

---

What Pushes Price Down

1. Generic entry and manufacturer competition. From 2013 to 2017, generic eye drops had a median price decrease of 20% while branded eye drops had a median price increase of 44%. The more FDA-approved generic manufacturers enter a molecule, the faster acquisition cost falls. Glaucoma generics (latanoprost, timolol, dorzolamide) now trade well below $20 per bottle in competitive GPO tiers.

2. Biosimilars for anti-VEGF agents. In February 2025, Teva entered into a strategic collaboration to commercialize FYB203, a biosimilar candidate for Eylea (aflibercept), in most parts of Europe; the biosimilar, branded as AHZANTIVE, is developed by Formycon. U.S. biosimilar aflibercept entrants are expected to exert significant downward pressure on the branded Eylea franchise, which still generated USD 6.8 billion in 2024, though biosimilar entrants and Medicare negotiations impose pricing tension.

3. Off-label compounded bevacizumab. At ~$55–$60 per dose versus $1,850–$2,000 for branded anti-VEGF agents, compounded bevacizumab is the single largest cost-reduction lever available to retina programs. Aflibercept and ranibizumab are approximately 31 and 20 times more expensive than bevacizumab, respectively. Compounding pharmacies must meet FDA sterility standards (21 CFR 503B for outsourcing facilities); verify 503B registration before sourcing.

4. GPO and 340B pricing. Hospitals qualifying under Section 340B of the Public Health Service Act can access federally mandated ceiling prices on covered outpatient drugs — including most branded ophthalmic agents — at discounts of 25–50% below WAC. GPO contracts (Vizient, Premier, HealthTrust) typically yield 10–30% below WAC for non-340B facilities.

5. Formulary standardization. If brand-name ophthalmic drugs were substituted by generic and therapeutic equivalents, $882 million in total savings would be generated — a figure from a Medicare analysis of the ophthalmic market.

---

Hidden Costs

• Administration and procedure fees. Intravitreal injection facility and professional fees range from $150–$500 per encounter under Medicare Part B, separate from drug acquisition cost. For a patient receiving 8 injections per year, that is an additional $1,200–$4,000 in non-drug costs.

• Cold chain and storage. Anti-VEGF biologics (aflibercept, ranibizumab, faricimab) require refrigeration at 2–8°C. Validated pharmacy refrigerators meeting USP <1> standards cost $2,000–$8,000. Temperature excursion events that compromise product require full-vial write-offs at $1,850+ per unit.

• Sterility and compounding compliance. Ophthalmic drug products, such as eye drops, pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses; any drug used in the eyes must be sterile to reduce the risk of infection. If your institution uses compounded bevacizumab, ongoing USP <797> compliance audits and testing add $5,000–$20,000 per year in pharmacy infrastructure costs.

• Waste from partial-vial use. Anti-VEGF vials are single-use; any remaining drug after draw must be discarded. At $1,850–$2,000 per vial, even 10% waste from imprecise draw technique represents $185–$200 per wasted vial.

• Recall and quality risk. By mid-November 2023, the FDA had issued warnings to consumers to stop using 29 over-the-counter eye drops due to potential risk of eye infections; manufacturers found to have unsanitary conditions included products sold by CVS, Rite Aid, Target, and Walmart. Recall exposure for formulary products includes replacement cost and patient monitoring.

• USP quality testing. Ophthalmic drug products with names recognized in the USP are generally required to meet particulate matter requirements in USP General Chapter <771> Ophthalmic Products — Quality Tests. Institutions sourcing from compounding pharmacies bear the cost of independent sterility and particulate testing.

---

How to Negotiate

1. Invoke biosimilar competition at the contract renewal table. With multiple aflibercept biosimilars now entering or approaching U.S. approval, use their existence as leverage to reduce branded aflibercept contract pricing — even before institutional conversion. Manufacturers prefer discounted volume retention over lost accounts.

2. Request tiered rebates tied to injection volume. High-volume retina centers (500+ injections/year) can often negotiate volume-tiered rebates from Regeneron, Roche/Genentech, and Novartis. Ensure rebates are structured on net acquisition cost, not WAC, and that rebate accrual timelines are 90 days or less.

3. Bundle topical and biologic contracts with the same distributor. Distributors (McKesson, AmerisourceBergen, Cardinal Health) often provide deeper line-item discounts when a facility consolidates its total ophthalmic spend — topicals and biologics together — under one agreement.

4. Use 340B ceiling price calculators before signing any branded contract. If your facility is 340B-eligible, the Apexus ceiling price database (restricted access) will show the federal ceiling. Any contract price above ceiling is non-compliant. If not 340B-eligible, use GPO benchmarks as your floor.

5. Standardize to one anti-VEGF agent per indication tier. Formulary fragmentation across ranibizumab, aflibercept, and faricimab simultaneously eliminates volume leverage on all three. A tiered protocol (compounded bevacizumab first-line, branded agent for non-responders) concentrates spend and strengthens the negotiation position with the branded manufacturer.

6. Negotiate multi-year pricing locks with biosimilar escape clauses. Lock in branded pricing for 12–24 months, but include a clause that allows conversion to biosimilar equivalents at any time without penalty. Manufacturers will often accept this to secure the contract.

---

When the Price Feels Off

• A compounded bevacizumab price significantly below $40/dose should prompt verification of the supplier's 503B outsourcing facility registration with FDA. Unregistered compounders do not meet federal sterility standards, and contaminated lots have caused endophthalmitis outbreaks.

• A branded anti-VEGF at more than 5% above published WAC from your current distributor warrants renegotiation; WAC is public, and distributor margin on biologics is typically 2–4%.

• "GPO pricing" on a branded topical that is within 10% of retail pharmacy WAC is not a GPO discount — it is standard distribution pricing dressed up as a contract benefit. Verify against the GPO's published contract pricing portal directly.

• Preservative-free generics priced identically to preserved generics from the same manufacturer likely indicates a supply consolidation tactic. PF generics do carry higher manufacturing cost, but not identically to branded — a 10–30% PF premium over preserved generic WAC is defensible; parity pricing is not.

• Rapid price increases on established branded topicals without new clinical data or reformulation are well-documented in the ophthalmic sector. Eye care providers hold the highest proportion of brand-name drug claims when compared to other provider types, and the rise in ophthalmic drug expenses may be explained by increasing branded drug prices absent corresponding clinical differentiation.

---

Sources

1. American Academy of Ophthalmology (AAO), EyeNet: "Expensive Drugs" — aflibercept ($1,850/dose) and ranibizumab ($1,950–$2,023/dose) WAC data. aao.org

2. Meer E, Oh D, Brodie F — Clinical Ophthalmology (PubMed Central, PMC9792116): "Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration." Wholesale acquisition cost comparisons across faricimab, aflibercept, ranibizumab over a 3-year horizon.

3. DRCR.net / Glassman et al. — JAMA Ophthalmology 2016 (PMC6648661): "Cost-Effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for DME." Published 2015 WAC figures: aflibercept $1,850, ranibizumab $1,170, compounded bevacizumab ~$60/dose.

4. Bliss et al. — PMC8478971 (2021): "The Effect of Market Competition on the Price of Topical Eye Drops." FDA Orange Book and National Average Drug Acquisition Cost database analysis, 2013–2017. Median generic price change (–20%) vs. branded (+44%).

5. U.S. Pharmacopeia (USP) — Quality Matters blog: FDA's Draft Guidance on Topical Ophthalmic Drug Products and USP General Chapter <771> Ophthalmic Products — Quality Tests. qualitymatters.usp.org

6. FDA Center for Drug Evaluation and Research (CDER) — "What You Should Know About Eye Drops." Sterility requirements and OTC vs. Rx regulatory distinctions. fda.gov

---

This article reflects publicly available pricing as of Q2 2025. MedSource will update pricing ranges as institutional quote data is collected. Contact us to submit your ophthalmic pharmaceutical quote for inclusion in our aggregate database.